Qiagen Acquires DxS
- Posted on 09 October 2009
Qiagen has acquired DxS, a privately-held developer and manufacturer of companion diagnostic products headquartered in Manchester, UK. The transaction is valued at approximately US$95 million in cash, plus up to an additional US$35 million if specified commercial and other milestones are met.
Qiagen revealed that the combined company is active in over 15 collaborations with pharmaceutical companies to market and/or develop companion diagnostic products. The programs span genetic, expression, epigenetic and other markers.
